



- | | |
|---|--|
| <p>(51) International Patent Classification:
 <i>A61K 47/68</i> (2017.01) <i>A61P 35/00</i> (2006.01)
 <i>A61K 38/05</i> (2006.01) <i>A61K 39/00</i> (2006.01)</p> | <p>(72) Inventors: SIEVERS, Eric; 1690 El Camino Del Teatro, La Jolla, California 92037 (US). MARTIN, Philippe; 2610 Inyaha Lane, La Jolla, California 92037 (US).</p> |
| <p>(21) International Application Number:
 PCT/US2021/058747</p> | <p>(74) Agent: DUNLEAVY, Kevin J.; Mendelsohn Dunleavy, P.C., 1500 John F. Kennedy Blvd. Suite 910, Philadelphia, Pennsylvania 19102 (US).</p> |
| <p>(22) International Filing Date:
 10 November 2021 (10.11.2021)</p> | <p>(81) Designated States (<i>unless otherwise indicated, for every kind of national protection available</i>): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,</p> |
| <p>(25) Filing Language: English</p> | |
| <p>(26) Publication Language: English</p> | |
| <p>(30) Priority Data:
 63/113,040 12 November 2020 (12.11.2020) US</p> | |
| <p>(71) Applicant: BIOATLA, INC. [US/US]; 11085 Torreyana Road, Suite 100, San Diego, California 92121 (US).</p> | |

(54) Title: METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES




FIG. 1A

(57) Abstract: Methods for treatment of Axl-expressing cancers are provided. The methods involve administering to a subject in need thereof, a polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein, antibodies or antibody fragments containing the polypeptide, and/or an immunoconjugate compound thereof. The immunoconjugate compound is a Conditionally Active Biologic (CAB) anti-Axl antibody conjugated to one or more drug(s) via a cleavable linker (CAB-Axl-ADC). The immunoconjugate is a mAbBA3011-cleavable linker-MMAE_(n) or pharmaceutically acceptable salt thereof, in which the mAbBA3011 is an antibody or antibody fragment, the MMAE is monomethyl auristatin E, and the (n) is an integer between 1 and 4.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.